Tuesday, October 26, 2010: 2:30 PM
Sheraton Hall E/F (Sheraton Centre Toronto Hotel)
* Candidate for the Lee B. Lusted Student Prize Competition
Click here to view Poster Number Acronyms
Poster Board / Category
2
QMA
*
OPTIMAL COLONOSCOPY SCREENING POLICIES FOR COLORECTAL CANCER PREVENTION AND SURVEILANCE
Fatih S. Erenay, MS1, Oguzhan Alagoz, PhD2 and Adnan Said, MD1, (1)University of Wisconsin, Madison, WI, (2)University of Wisconsin-Madison, Madison, WI
3
QMA
REDUCING EMERGENCY DEPARTMENT WAIT TIMES: INSIGHTS FROM MATHEMATICAL MODELING
Morgan E. Lim, BHSc, MA1, Tim J. Nye, PhD2, James M. Bowen, BScPhm, MSc2, Ron Goeree, MA2 and Jean-Eric Tarride, PhD, MA2, (1)McMaster University, Programs for Assessment of Technolgy in Health (PATH) Research Institute, Hamilton, ON, Canada, (2)McMaster University, Hamilton, ON, Canada
6
HTA
THE COST-EFFECTIVENESS ANALYSIS OF FIVE NON-INVASIVE CARDIAC IMAGING TECHNOLOGIES IN ONTARIO
Luciano Ieraci, MSc1, Mike Paulden, MA., MSc.1, Gabrielle van der Velde, DC, PhD1, Harindra C. Wijeysundera, MD2, Márcio Machado, PhD1, William Witteman, MISt1 and Murray D. Krahn, MD, MSc1, (1)University of Toronto, Toronto, ON, Canada, (2)Schulich Heart Center, Sunnybrook Health Sciences Center, Toronto, ON, Canada
7
HTA
POLYMERASE CHAIN REACTION TESTS FOR METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN HOSPITALIZED PATIENTS: CLINICAL AND COST-EFFECTIVENESS ANALYSES
Julie Polisena1, Stephen Membe1, Stella Chen1, Therese Leroux2, Karen Cimon1, Sarah McGill1, Kevin Forward3 and Michael Gardam4, (1)Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, (2)Universite de Montreal, Montreal, QC, Canada, (3)Dalhousie University, Halifax, NS, Canada, (4)University Health Network, Toronto, ON, Canada
9
HTA
NON-INVASIVE CARDIAC IMAGING TECHNOLOGIES FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE: A MEGA-HTA TO INFORM POLICY DECISION MAKING
Bronwen McCurdy, B.Sc., MPH, Tanya Khan, MHSc, Alexandra Chambers, M.Sc., Jacob Franek, MHSc and Kristen McMartin, Ph.D., Ontario Ministry of Health and Long-Term Care, Toronto, ON, Canada
10
HTA
COMPARATIVE EFFECTIVENESS RESEARCH: ERECTILE DYSFUNCTION LONGITUDINAL OUTCOMES AND COSTS ACROSS TREATMENTS FOR PROSTATE CANCER
Leslie S. Wilson, PhD1, Rituparna Basu, Ph.D.1, Carly J. Paoli, Pharm.D.1, Vivian Lian, Pharm, D, student1, Natalia Sadesky, MS, PHD2, Matthew Cooperberg, MD1 and Peter Carroll, MD, Ph.D1, (1)University of California San Francisco, San Francisco, CA, (2)UCSF, San Francisco, CA
11
HTA
ECONOMIC EVALUATION OF GENETIC TEST IN COMBINATION WITH PREVENTIVE DONEPEZIL TREATMENT FOR AMNESTIC MILD COGNITIVE IMPAIRMENT (AMCI) PATIENTS
Jaclyn M. Beca1, Sandjar Djalalov, PhD2, Jean Hai Ein Yong, MASc3, Sandra Black, MA, MD4, Gustavo Saposnik, MD2, Michael Mendelson5, Katherine Siminovitch, MD6, Myla E. Moretti, M.Sc.7, Sukirtha Tharmalingam, M.Sc8 and Jeffrey Hoch, PhD3, (1)St. Michael's, Toronto, ON, Canada, (2)St. Michael's Hospital, Toronto, ON, Canada, (3)Cancer Care Ontario, Toronto, ON, Canada, (4)Sunnybrook Health Sciences Centre, Toronto, ON, Canada, (5)Caledon Institute of Social Policy, Ottawa, ON, Canada, (6)Mount Sinai Hospital, Toronto, ON, Canada, (7)University of Toronto, Toronto, ON, Canada, (8)Sunnybrook Hospital, Toronto, ON, Canada
12
HTA
IMPLEMENTING GUIDELINES INTO CLINICAL PRACTICE: WHAT IS THE VALUE?
Ties Hoomans, PhD1, Andre Ament, PhD1, Silvia Evers, PhD1 and Hans Severens, PhD2, (1)Maastricht University, Maastricht, Netherlands, (2)Erasmus University Rotterdam, Rotterdam, Netherlands
13
HTA
THE FIRST 4 YEARS OF A HOSPITAL-BASED COMPARATIVE EFFECTIVENESS CENTER: TRANSLATING RESEARCH INTO PRACTICE TO IMPROVE THE QUALITY, SAFETY AND COST-EFFECTIVENESS OF PATIENT CARE
Matthew D. Mitchell, PhD, Kendal Williams, MD, MPH and Craig A. Umscheid, MD, MSCE, University of Pennsylvania Health System, Philadelphia, PA
15
GLH
A SYSTEMATIC REVIEW OF THE INCIDENCE AND ECONOMIC BURDEN OF SURGICAL SITE INFECTION IN KOREA
Jonathan T. Tan, Ph.D1, Kristina Coleman, Ph.D, MPH1, Sarah Norris, Ph.D1 and Laurent Metz, MD, -, MBA, -, MS2, (1)Health Technology Analysts Pty Ltd, Balmain, Australia, (2)Johnson & Johnson, Singapore, Singapore
16
HSR
*
WHEN SHOULD END-STAGE LIVER DISEASE (ESLD) PATIENTS UPDATE THEIR MODEL FOR END-STAGE LIVER DISEASE (MELD) SCORE?
Z. Gozde Icten, MS1, Lisa Maillart, PhD2, Andrew Schaefer, PhD2, Atul Bhandari, PhD3 and Mark S. Roberts, MD, MPP4, (1)Industrial Engineering Department, Pittsburgh, PA, (2)University of Pittsburgh, Pittsburgh, PA, (3)SmartOps Coorporation, Pittsburgh, PA, (4)University of Pittsburgh School of Medicine, Pittsburgh, PA
17
HSR
TEN PERCENT OR GREATER WEIGHT LOSS IS A CLINICALLY MEANINGFUL OUTCOME IN THE TREATMENT OF OBESITY
Cheryl S. Hankin, PhD1, Amy Bronstone, PhD1 and Barbara Troupin, MD, MBA2, (1)BioMedEcon, Moss Beach, CA, (2)VIVUS, Inc., Mountain View, CA
18
HSR
*
PERFORMANCE OF HEAD CIRCUMFERENCE PERCENTILE CUTOFFS
Carrie Daymont, MD1, Moira Zabel, MD2, Chris Feudtner, MD, MPH, PHD3 and David Rubin, MD, MSCE3, (1)University of Manitoba, Winnipeg, MB, Canada, (2)Children's National Medical Center, Washington, DC, (3)University of Pennsylvania, Philadelphia, PA
20
HSR
A COST COMPARISON OF OPTIMAL VERSUS SUB-OPTIMAL PRE-DIALYSIS CARE IN CANADA BASED ON THE STARRT TRIAL
Charles Piwko, PhD1, Farah Jivraj, BSc, MSc2, Lou Marra, PhD3, Eva Appel, BSc1, Jacob Wolpin, PhD1, Fernando Camacho, PhD4, Colin Vicente, MSc1, David C. Mendelssohn, MD, FRCPC5 and Phil A. McFarlane, MD, FRCPC6, (1)PIVINA Consulting Inc., Thornhill, ON, Canada, (2)Janssen-Ortho Inc., Toronto, ON, Canada, (3)Janssen Ortho Inc., Toronto, ON, Canada, (4)DAMOS Inc., Toronto, ON, Canada, (5)Humber River Regional Hospital and University of Toronto, Toronto, ON, Canada, (6)St. Michael's Hospital Toronto and University of Toronto, Toronto, ON, Canada
21
HTA
*
COST-EFFECTIVENESS ANALYSIS OF 48- VERSUS 24-HOUR METHYLPREDNISOLONE INTERVENTION IN SPINAL CORD INJURY PATIENTS
Gwen Schwartz1, Carlos Ruiz1, José Carlos Ferreira1, Ori D. Rotstein2, Jeffrey S. Hoch1 and Peter C. Coyte1, (1)University of Toronto, Toronto, ON, Canada, (2)St. Michael's Hospital and University of Toronto, Toronto, ON, Canada
22
HSR
*
PUBLISHED ECONOMIC EVIDENCE TO SUPPORT PERSONALIZED MEDICINE DECISION-MAKING: THE EXAMPLE OF HER2-POSITIVE EARLY BREAST CANCER
Ilia Ferrusi, BSc1, Deborah Marshall, PhD2, Nathalie A. Kulin, MSc2 and Natasha Leighl, MD, MSc3, (1)Centre for Evaluation of Medicines, Hamilton, ON, Canada, (2)University of Calgary, Calgary, AB, Canada, (3)University of Toronto, Toronto, ON, Canada
24
HSR
COST-EFFECTIVENESS ANALYSIS OF DULOXETINE AND VENLAFAXINE EXTENDED RELEASE FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD)
Sonam Mehta, BS1, Ayush V. Patel, BS1 and Sujit S. Sansgiry, PhD2, (1)University of Houston, Houston, TX, (2)College of Pharmacy, University of Houston, Houston, TX
26
HSP
BRIDGING MULTICRITERIA DECISION ANALYSIS (MCDA) WITH HEALTH TECHNOLOGY ASSESSMENT (HTA) FOR POLICY AND CLINICAL DECISIONMAKING: CASE STUDIES IN CANADA AND SOUTH AFRICA
Mireille M. Goetghebeur, PhD1, Cheri Deal, MD, PhD2, Jacqui Miot, PhD3, Michele Tony, BSc1, Monika Wagner, PhD1, Hanane Khoury, PhD1, Donna Rindress, PhD1 and Paul Oh, MD4, (1)BioMedCom Consultants inc, Montreal, QC, Canada, (2)Centre Hospitalier Universitaire Ste-Justine, Montreal, QC, Canada, (3)University of Pretoria, Pretoria, South Africa, (4)Toronto Rehabilitation Institute, Toronto, ON, Canada
27
JDM
PHARMCOGENETIC TESTING AND EVIDENCE-BASED DECISION-MAKING IN ONTARIO: THE APPLICATION OF ONTARIO'S DECISION DETERMINANTS FRAMEWORK TO THE EVALUATION OF PHARMACOGENETIC TESTS
Michelle Bornstein, MSc1, Wendong Chen, MD, PhD2, Jacob Franek, MHSC3, Luciano Ieraci, MSc2, Murray D. Krahn, MD, MSc2, Hamid Nakai-Pour, MD, Ph.D1, Nicole Onetto, MD4, Margie Parthimos, Ph.D.1, Mike Paulden, MA., MSc.2 and Leslie Levin, MD1, (1)Ministry of Health and Long-Term Care, Toronto, ON, Canada, (2)University of Toronto, Toronto, ON, Canada, (3)Ontario Ministry of Health and Long-Term Care, Toronto, ON, Canada, (4)Ontario Institute of Cancer Research, Toronto, ON, Canada
28
JDM
DO PHYSICIANS OF PRIMARY CARE HOSPITALS LIMIT THE ACCESS OF ALCOHOLIC PATIENTS TO LIVER TRANSPLANTATION (LT)?
Gwenaelle Vidal-Trecan, MD, PhD, Université Paris Descartes, Faculté de médecine, AP-HP, Paris, France, Daniella Randriamanana, MD, Université Paris Descartes, Paris, France, Filomena Conti, MD, PhD, Hôpital Saint Antoine, AP-HP, Paris, France and Yvon Calmus, MD, PhD, Hôpital Saint Antoine, Paris, France
29
JDM
DECISION AIDS NEAR THE END-OF-LIFE, A PILOT RANDOMIZED CONTROLLED TRIAL AND QUALITATIVE EXIT INTERVIEWS
Dan D. Matlock, MD1, Tarah Keech, MS2, Carolyn Nowels, MSPH1, Jean S. Kutner, MD, MSPH1 and Marlene McKenzie, RN2, (1)The University of Colorado Denver, Aurora, CO, (2)University of Colorado Denver, Aurora, CO
31
JDM
INTERSTIM® SACRAL NEUROMODULATION AND BOTOX® BOTULINUM-A TOXIN INTRADETRUSOR INJECTIONS FOR REFRACTORY URGE URINARY INCONTINENCE: A DECISION ANALYSIS COMPARING OUTCOMES INCLUDING EFFICACY AND COMPLICATIONS
Kenneth J. Smith, MD, MS, Jonathan P. Shepherd, MD, MSc and Jerry L. Lowder, MD, MSc, University of Pittsburgh, Pittsburgh, PA
32
JDM
CAPTURING THE PERCEPTIONS OF CANCER PATIENTS TO GUIDE THE DESIGN OF DECISION AIDS THAT INCORPORATE EVIDENCE ABOUT COMPARATIVE EFFECTIVENESS
Karen B. Eden, PhD1, Anais Tuepker, PhD, MPH2 and David H. Hickam, MD, MPH1, (1)Oregon Health and Science University, Portland, OR, (2)Portland VA Medical Center, Portland, OR
33
JDM
INVERSE PREFERENCE ELICITATION FOR DYNAMIC TREATMENT REGIMES
Daniel J. Lizotte, PhD1, Michael Bowling, PhD2 and Susan A. Murphy1, (1)University of Michigan, Ann Arbor, MI, (2)University of Alberta, Edmonton, AB, Canada
34
JDM
BREASTHEALTHDECISIONS.ORG: RISK ASSESSMENT AND DECISION SUPPORT FOR BREAST CANCER PREVENTION
Elissa M. Ozanne, PhD1, Sarah Boortz2, Tom Bechtold2 and Laura J. Esserman, MD, MBA2, (1)Harvard Medical School, Boston, MA, (2)University of California, San Francisco, San Francisco, CA
35
JDM
*
THE SCRIPT CONCORDANCE TEST: A NEW TOOL TO EVALUATE CONTINUING PROFESSIONAL DEVELOPMENT TRAINING IN SHARED DECISION MAKING FOR THE USE OF ANTIBIOTICS FOR ACUTE RESPIRATORY INFECTIONS
Anik Giguere, PhD1, Michel Labrecque, MD, PhD1, Pierre-Olivier H.Mercier, MSc, DESS2, Merlin Njoya, MSc3 and France Légaré, MD, PhD1, (1)CHUQ Research Center-Hospital St-François d'Assise, Knowledge Transfer and Health Technology Assessment, Quebec, QC, Canada, (2)Association pour les Ingrédients Santé en Alimentation, Quebec, QC, Canada, (3)CHUQ Research Center-Hospital St-François d'Assise, Quebec, QC, Canada
36
JDM
THE PAST MAY DISAMBIGUATE THE PRESENT: PRIOR EXPERIENCE LEADS TO UNAMBIGUOUS INTERPRETATIONS OF AMBIGUOUS MEDICAL SYMPTOMS IN NOVICES
Meredith E. Young, PhD1, Lee R. Brooks, PhD2, Elizabeth Howey, BSc.2 and Geoffrey R. Norman, PhD2, (1)McGill University, Montreal, QC, Canada, (2)McMaster University, Hamilton, ON, Canada
37
JDM
PERSONALIZED PREVENTIVE MEDICINE AND ITS CONSEQUENCES: THE IMPACT OF PREDICTIVE GENOMIC TESTING ON RISK PERCEPTION AND WORRY
Katherine M. James, MPH, Jon C. Tilburt, MD, MPH, Katrin R. Frimannsdottir, PhD, Pamela S. Sinicrope, DrPH, Barbara A. Koenig, PhD and Clayton T. Cowl, MD, MS, Mayo Clinic, Rochester, MN
38
JDM
*
DO SURGEONS FOSTER SHARED DECISION MAKING IN THEIR COMMUNICATION WITH PATIENTS ABOUT THEIR ABDOMINAL AORTIC ANEURYSM?
Anouk M. Knops, MSc, Dirk T. Ubbink, MD, PhD, Dink A. Legemate, MD, PhD, Hanneke C.J.M. de Haes, PhD and Astrid Goossens, PhD, Academic Medical Center, Amsterdam, Netherlands
39
JDM
BREAST CANCER TREATMENT DECISIONS AMONG WOMEN AGED 80 AND OLDER
Mara Schonberg, MD, MPH, Beth Israel Deaconess Medical Center, Harvard Medical School, Brookline, MA, Rebecca Silliman, MD, PhD, Boston University, Boston, MA and Edward R. Marcantonio, Division of General Medicine and Primary Care, Brookline, MA
40
JDM
EXPLORING DIETITIANS' SALIENT BELIEFS TO ADOPT SHARED DECISION MAKING-SPECIFIC BEHAVIOURS
Sarah-Maude Deschênes, RD, master, candidate1, Annie Lapointe, RD, PhD2, France Légaré, MD, PhD3, Marie-Pierre Gagnon, PhD1 and Sophie Desroches, RD, PhD4, (1)Université Laval, Québec, QC, Canada, (2)CHUQ Research Center-Hospital St-François d'Assise, Québec, QC, Canada, (3)CHUQ Research Center-Hospital St-François d'Assise, Knowledge Transfer and Health Technology Assessment, Quebec, QC, Canada, (4)Université Laval; CHUQ Research Center-Hôpital St-François d'Assise, Quebec, QC, Canada
42
JDM
*
TOWARDS PREFERENCE-CONGRUENT CARE AT THE END OF LIFE: A MARKOV MODEL TO INFORM ADVANCE DIRECTIVE DECISIONS FOR PATIENT WITH COPD
Negin Hajizadeh, MD, MPH, Yale University School of Medicine, New Haven, CT and R. Scott Braithwaite, MD, MSc, FACP, New York University School of Medicine, New York, NY
43
JDM
OBSERVED VERSUS RECOMMENDED PATIENT PRESCRIPTION REFILL BEHAVIOUR - ASSESSMENT OF ADALIMUMAB AND ETANERCEPT PRESCRIPTION GAPS FOR THE FIRST YEAR OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
CT Carter1, O. Tunceli2, SC Bolge1, L. Denny1, C. Fang2, MP Ingham, MSc3 and S. Kamat2, (1)Centocor Ortho Biotech Inc, Horsham, PA, (2)HealthCore Inc, Wilmington, DE, (3)Centocor Ortho Biotech Inc., Horsham, PA
44
JDM
RISK AND UNCERTAINTY: SHIFTING DECISION-MAKING FOR ANEUPLOIDY SCREENING TO THE FIRST TRIMESTER OF PREGNANCY
Ruth M. Farrell, MD, MA1, Natasha Dolgin, BA1, Christian Simon, PhD2, Victoria A. Winbush, PhD, MPH, LiSW3, Susan A. Flocke, PhD3 and Mary Beth Mercer, MPH1, (1)Cleveland Clinic, Cleveland, OH, (2)University of Iowa, Iowa City, IA, (3)Case Western Reserve University, Cleveland, OH
45
JDM
TO HAVE OR NOT TO HAVE PSA TEST? IS THE DECISION AFFECTED BY WHETHER INFORMATION IS PRESENTED SEQUENTIALLY VS. ALL-AT-ONCE?
Teresa Gavaruzzi, PhD1, Brian J. Zikmund-Fisher, PhD2, Lorella Lotto1, Peter A. Ubel, MD3 and Angela Fagerlin, PhD3, (1)University of Padova, Padova, Italy, (2)University of Michigan, Ann Arbor, MI, (3)VA Ann Arbor Healthcare System & University of Michigan, Ann Arbor, MI
48
JDM
TREATING HIP AND KNEE OSTEOARTHRITIS: DO PATIENTS WHO CHOOSE SURGERY MAKE BETTER DECISIONS?
Sandra Feibelmann, M.P.H.1, Theresa Yang, BA1, Jeffrey N. Katz, MD, MS2, Catharine F. Clay, MA, BSN3, Stephen Kearing, MS4 and Karen R. Sepucha, PhD1, (1)Massachusetts General Hospital, Boston, MA, (2)Brigham and Women's Hospital, Boston, MA, (3)Dartmouth Hitchcock Medical Center, Lebanon, NH, (4)Dartmouth Medical School, Lebanon, NH
49
JDM
*
EFFECTS OF DELAYS IN GLYCEMIC CONTROL ON COMPLICATIONS IN MIDDLE-AGED ADULTS WITH NEW ONSET DIABETES
Neda Laiteerapong, MD, Priya M. John, MPH, David O. Meltzer, MD, PhD and Elbert S. Huang, MD, MPH, University of Chicago, Chicago, IL
51
JDM
HOW MANY MORE PATIENTS WILL WE TREAT BY DECREASING THE THRESHOLD?
Rudy Bruyninckx, MD1, Bert Aertgeerts, PhD1, Frank Buntinx, PhD2 and Jef Van den Ende, PhD3, (1)Katholieke Universiteit Leuven, Leuven, Belgium, (2)Research Institute Caphri, Universiteit Maastricht, Maastricht, Netherlands, (3)Institute of Tropical Medicine, Antwerp, Belgium
52
JDM
FOUNDATIONAL KNOWLEDGE IMPROVES LEARNING IN A SIMULATED CLINICAL TRAINING SCENARIO
John Paul Minda, Ph., D., The University of Western Ontario, London, ON, Canada, Mark Goldszmidt, M.D., Schulich School of Medicine & Dentistry, The University of Western Ontario, London, ON, Canada and Aimee Skye, Ph., D., Grant MacEwan University, Edmonton, AB, Canada
53
JDM
A REGRET THEORY APPROACH TO DECISION CURVE ANALYSIS
Iztok Hozo, PhD, Indiana University Northwest, Gary, IN, Athanasios Tsalatsanis, Ph.D., USF Health, Tampa, FL, Andrew Vickers, Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY and Benjamin Djulbegovic, MD, PhD, University of South Florida & H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
54
JDM
*
POORLY PERCEIVED PERSONAL ACCOUNTABILITY: INFECTION CONTROL'S MISSING LINK?
Matan J. Cohen, MD, MPH1, Oren Zimhony, MD2, Shmuel Benenson, MD1, Maytal Nahari, RN1, Aviva Weiss, B.Med.Sci1 and Mayer Brezis, MD, MPH1, (1)Hadassah-Hebrew University Medical Center, Jerusalem, Israel, (2)Kaplan Medical Center, affiliated with the Hebrew University, Rehovot, Israel
55
JDM
SHARED DECISION MAKING FOR WOMEN WITH BREAST CANCER: KNOWLEDGE, VALUES, AND DECISIONAL CONFLICT OVER TIME
Stephen Kearing, MS1, Dale Collins Vidal, MD, MS2, Catharine F. Clay, MA, BSN2, Allison J. Hawke1, Alyssa S. Stevens, BS2, Susan Berg, MS, CGC2, Gary N. Schwartz2, Peter Kaufman, MD2, Bradley A. Arrick2 and Hilary A. Llewellyn-Thomas, PhD1, (1)Dartmouth Medical School, Lebanon, NH, (2)Dartmouth Hitchcock Medical Center, Lebanon, NH
56
JDM
DO TESTIMONIALS IN A COLON CANCER SCREENING DECISION AID INFLUENCE PATIENT DECISION MAKING?
W. Blair Brooks, MD1, Kisha T. Weiser, MD, MPH1, Charles Brackett, MD, MPH1, Martha Coutermarsh, RN1 and Stephen Kearing, MS2, (1)Dartmouth-Hitchcock Medical Center, Lebanon, NH, (2)Dartmouth Medical School, Lebanon, NH
57
JDM
CONTRACEPTIVE DECISIONAL CONFLICT: A QUALITATIVE ANALYSIS APPLYING THE OTTAWA DECISION SUPPORT FRAMEWORK TO ASSESS DETERMINANTS OF CONTRACEPTIVE DECISIONS
Bryna Harwood, MD, MS, Nadine Peacock, PhD, Kenya McRae, JD, MBA, MPH, Alan Schwartz, PhD and Stacie Geller, PhD, University of Illinois at Chicago, Chicago, IL
